{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:25Z","timestamp":1792091365671,"version":"4.4.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006545","name":"NIMHD","doi-asserted-by":"crossref","award":["U54MD007584"],"award-info":[{"award-number":["U54MD007584"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30304-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:35:40Z","timestamp":1764768940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19"],"prefix":"10.1038","volume":"16","author":[{"given":"Angela","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Agsalda-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya Anil","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks I.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Asante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chiang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah V.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malia L.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"DelMundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic C.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Shikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan G.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"30304_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41588-020-00759-x","volume":"53","author":"C Blume","year":"2021","unstructured":"Blume, C. et al. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat. Genet. 53, 205\u2013214. https:\/\/doi.org\/10.1038\/s41588-020-00759-x (2021).","journal-title":"Nat. Genet."},{"key":"30304_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"F Scialo","year":"2020","unstructured":"Scialo, F. et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung 198, 867\u2013877. https:\/\/doi.org\/10.1007\/s00408-020-00408-4 (2020).","journal-title":"Lung"},{"key":"30304_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.7150\/ijms.46695","volume":"17","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int. J. Med. Sci. 17, 1522\u20131531. https:\/\/doi.org\/10.7150\/ijms.46695 (2020).","journal-title":"Int. J. Med. Sci."},{"key":"30304_CR4","doi-asserted-by":"publisher","first-page":"e9610","DOI":"10.15252\/msb.20209610","volume":"16","author":"F Hikmet","year":"2020","unstructured":"Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610. https:\/\/doi.org\/10.15252\/msb.20209610 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"30304_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016-1035.e19. https:\/\/doi.org\/10.1016\/j.cell.2020.04.035 (2020).","journal-title":"Cell"},{"key":"30304_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41588-020-00732-8","volume":"52","author":"KW Ng","year":"2020","unstructured":"Ng, K. W. et al. Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option. Nat. Genet. 52, 1294\u20131302. https:\/\/doi.org\/10.1038\/s41588-020-00732-8 (2020).","journal-title":"Nat. Genet."},{"key":"30304_CR7","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.biopha.2021.111363","volume":"137","author":"ME Mehrabadi","year":"2021","unstructured":"Mehrabadi, M. E. et al. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. Biomed. Pharmacother. 137, 111363. https:\/\/doi.org\/10.1016\/j.biopha.2021.111363 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"30304_CR8","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3390\/cells10102755","volume":"10","author":"F Pucci","year":"2021","unstructured":"Pucci, F., Annoni, F., Dos Santos, R. A. S., Taccone, F. S. & Rooman, M. Quantifying renin\u2013angiotensin\u2013system alterations in COVID-19. Cells 10, 2755. https:\/\/doi.org\/10.3390\/cells10102755 (2021).","journal-title":"Cells"},{"key":"30304_CR9","doi-asserted-by":"publisher","first-page":"117905","DOI":"10.1016\/j.lfs.2020.117905","volume":"256","author":"N Banu","year":"2020","unstructured":"Banu, N., Panikar, S. S., Leal, L. R. & Leal, A. R. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: Therapeutic implications. Life Sci. 256, 117905. https:\/\/doi.org\/10.1016\/j.lfs.2020.117905 (2020).","journal-title":"Life Sci."},{"key":"30304_CR10","unstructured":"Hill, R. D. & Vaidya, P. N. Angiotensin II receptor blockers (ARB). StatPearls (StatPearls Publishing, 2024)."},{"key":"30304_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11906-018-0900-0","volume":"20","author":"R Satou","year":"2018","unstructured":"Satou, R., Penrose, H. & Navar, L. G. Inflammation as a regulator of the renin\u2013angiotensin system and blood pressure. Curr. Hypertens. Rep. 20, 100. https:\/\/doi.org\/10.1007\/s11906-018-0900-0 (2018).","journal-title":"Curr. Hypertens. Rep."},{"key":"30304_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41577-021-00634-8","volume":"22","author":"Z Bekassy","year":"2022","unstructured":"Bekassy, Z., LopatkoFagerstr\u00f6m, I., Bader, M. & Karpman, D. Crosstalk between the renin\u2013angiotensin, complement and kallikrein\u2013kinin systems in inflammation. Nat. Rev. Immunol. 22, 411\u2013428. https:\/\/doi.org\/10.1038\/s41577-021-00634-8 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"30304_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0022-3565(24)29352-6","volume":"298","author":"P Gohlke","year":"2001","unstructured":"Gohlke, P. et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J. Pharmacol. Exp. Ther. 298, 62\u201370 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"30304_CR14","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1167\/iovs.06-0478","volume":"47","author":"T Kurihara","year":"2006","unstructured":"Kurihara, T. et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest. Ophthalmol. Vis. Sci. 47, 5545\u20135552. https:\/\/doi.org\/10.1167\/iovs.06-0478 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"30304_CR15","doi-asserted-by":"publisher","first-page":"111544","DOI":"10.1016\/j.biopha.2021.111544","volume":"138","author":"Z Molavi","year":"2021","unstructured":"Molavi, Z. et al. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomed. Pharmacother. 138, 111544. https:\/\/doi.org\/10.1016\/j.biopha.2021.111544 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"30304_CR16","doi-asserted-by":"publisher","first-page":"27344","DOI":"10.1021\/acsomega.0c03682","volume":"5","author":"J Ivanov","year":"2020","unstructured":"Ivanov, J. et al. Quantitative structure\u2013activity relationship machine learning models and their applications for identifying viral 3CLpro- and RdRp-targeting compounds as potential therapeutics for COVID-19 and related viral infections. ACS Omega 5, 27344\u201327358. https:\/\/doi.org\/10.1021\/acsomega.0c03682 (2020).","journal-title":"ACS Omega"},{"key":"30304_CR17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41467-023-37035-5","volume":"14","author":"GD Noske","year":"2023","unstructured":"Noske, G. D. et al. An in-solution snapshot of SARS-CoV-2 main protease maturation process and inhibition. Nat. Commun. 14, 1545. https:\/\/doi.org\/10.1038\/s41467-023-37035-5 (2023).","journal-title":"Nat. Commun."},{"key":"30304_CR18","doi-asserted-by":"publisher","first-page":"001558","DOI":"10.1099\/jgv.0.001558","volume":"102","author":"MK Roe","year":"2021","unstructured":"Roe, M. K. et al. Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. J. Gen. Virol. 102, 001558. https:\/\/doi.org\/10.1099\/jgv.0.001558 (2021).","journal-title":"J. Gen. Virol."},{"key":"30304_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5152\/TurkThoracJ.2018.18014","volume":"20","author":"\u0130 Y\u0131lmaz","year":"2019","unstructured":"Y\u0131lmaz, \u0130. Angiotensin-converting enzyme inhibitors induce cough. Turk. Thorac. J. 20, 36\u201342. https:\/\/doi.org\/10.5152\/TurkThoracJ.2018.18014 (2019).","journal-title":"Turk. Thorac. J."},{"key":"30304_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1345\/aph.17388","volume":"32","author":"GB Pylypchuk","year":"1998","unstructured":"Pylypchuk, G. B. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann. Pharmacother. 32, 1060\u20131066. https:\/\/doi.org\/10.1345\/aph.17388 (1998).","journal-title":"Ann. Pharmacother."},{"key":"30304_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1378\/chest.99.1.36","volume":"99","author":"JL Sebastian","year":"1991","unstructured":"Sebastian, J. L., McKinney, W. P., Kaufman, J. & Young, M. J. Angiotensin-converting enzyme inhibitors and cough: Prevalence in an outpatient medical clinic population. Chest 99, 36\u201339. https:\/\/doi.org\/10.1378\/chest.99.1.36 (1991).","journal-title":"Chest"},{"key":"30304_CR22","doi-asserted-by":"publisher","first-page":"29274","DOI":"10.1073\/pnas.2009875117","volume":"117","author":"K Sriram","year":"2020","unstructured":"Sriram, K., Loomba, R. & Insel, P. A. Targeting the renin\u2013angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. Proc. Natl. Acad. Sci. USA 117, 29274\u201329282. https:\/\/doi.org\/10.1073\/pnas.2009875117 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"30304_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1124\/jpet.106.104026","volume":"318","author":"LJ Murphey","year":"2006","unstructured":"Murphey, L. J. et al. Bradykinin and its metabolite bradykinin 1\u20135 inhibit thrombin-induced platelet aggregation in humans. J. Pharmacol. Exp. Ther. 318, 1287\u20131292. https:\/\/doi.org\/10.1124\/jpet.106.104026 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"30304_CR24","doi-asserted-by":"publisher","first-page":"9915","DOI":"10.1007\/s11033-022-07539-2","volume":"49","author":"DAB Rex","year":"2022","unstructured":"Rex, D. A. B., Vaid, N., Deepak, K., Dagamajalu, S. & Prasad, T. S. K. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol. Biol. Rep. 49, 9915\u20139927. https:\/\/doi.org\/10.1007\/s11033-022-07539-2 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"30304_CR25","doi-asserted-by":"publisher","first-page":"e32075","DOI":"10.7759\/cureus.32075","volume":"14","author":"M Jayasinghe","year":"2022","unstructured":"Jayasinghe, M. et al. A comprehensive review of bradykinin-induced angioedema versus histamine-induced angioedema in the emergency department. Cureus 14, e32075. https:\/\/doi.org\/10.7759\/cureus.32075 (2022).","journal-title":"Cureus"},{"key":"30304_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/187152509789105444","volume":"7","author":"JW Bryant","year":"2009","unstructured":"Bryant, J. W. & Shariat-Madar, Z. Human plasma kallikrein\u2013kinin system: Physiological and biochemical parameters. Cardiovasc. Hematol. Agents Med. Chem. 7, 234\u2013250. https:\/\/doi.org\/10.2174\/187152509789105444 (2009).","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"30304_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/jci20805","volume":"114","author":"M Li","year":"2004","unstructured":"Li, M. et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J. Clin. Invest. 114, 112\u2013120. https:\/\/doi.org\/10.1172\/jci20805 (2004).","journal-title":"J. Clin. Invest."},{"key":"30304_CR28","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1016\/j.transproceed.2005.10.099","volume":"37","author":"JE Fildes","year":"2005","unstructured":"Fildes, J. E. et al. The effects of ACE inhibition on serum angiotensin II concentration following cardiac transplantation. Transplant. Proc. 37, 4525\u20134527. https:\/\/doi.org\/10.1016\/j.transproceed.2005.10.099 (2005).","journal-title":"Transplant. Proc."},{"key":"30304_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/hypertensionaha.111.202424","volume":"61","author":"S Park","year":"2013","unstructured":"Park, S. et al. Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension 61, 465\u2013471. https:\/\/doi.org\/10.1161\/hypertensionaha.111.202424 (2013).","journal-title":"Hypertension"},{"key":"30304_CR30","doi-asserted-by":"publisher","first-page":"e149834","DOI":"10.1172\/jci149834","volume":"133","author":"JY Tan","year":"2023","unstructured":"Tan, J. Y. et al. Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19. J. Clin. Invest. 133, e149834. https:\/\/doi.org\/10.1172\/jci149834 (2023).","journal-title":"J. Clin. Invest."},{"key":"30304_CR31","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/ijms25042061","volume":"25","author":"A Lu","year":"2024","unstructured":"Lu, A. et al. Hydroxypropyl-beta cyclodextrin barrier prevents respiratory viral infections: A preclinical study. Int. J. Mol. Sci. 25, 2061. https:\/\/doi.org\/10.3390\/ijms25042061 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"30304_CR32","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/s1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall, J. C. et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 20, e192\u2013e197. https:\/\/doi.org\/10.1016\/s1473-3099(20)30483-7 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"30304_CR33","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.15167\/2421-4248\/jpmh2020.61.3.1530","volume":"61","author":"Y Alimohamadi","year":"2020","unstructured":"Alimohamadi, Y., Sepandi, M., Taghdir, M. & Hosamirudsari, H. Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis. J. Prev. Med. Hyg. 61, e304\u2013e312. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2020.61.3.1530 (2020).","journal-title":"J. Prev. Med. Hyg."},{"key":"30304_CR34","doi-asserted-by":"publisher","first-page":"e26371","DOI":"10.1097\/md.0000000000026371","volume":"100","author":"JE Blair","year":"2021","unstructured":"Blair, J. E. et al. Mild to moderate COVID-19 illness in adult outpatients: Characteristics, symptoms, and outcomes in the first 4 weeks of illness. Medicine (Baltimore) 100, e26371. https:\/\/doi.org\/10.1097\/md.0000000000026371 (2021).","journal-title":"Medicine (Baltimore)"},{"key":"30304_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/biology12060843","volume":"12","author":"R Salom\u00e3o","year":"2023","unstructured":"Salom\u00e3o, R. et al. Involvement of matrix metalloproteinases in COVID-19: Molecular targets, mechanisms, and insights for therapeutic interventions. Biology (Basel) 12, 843. https:\/\/doi.org\/10.3390\/biology12060843 (2023).","journal-title":"Biology (Basel)"},{"key":"30304_CR36","doi-asserted-by":"publisher","first-page":"111785","DOI":"10.1016\/j.biopha.2021.111785","volume":"140","author":"S Patel","year":"2021","unstructured":"Patel, S. & Wadhwa, M. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomed. Pharmacother. 140, 111785. https:\/\/doi.org\/10.1016\/j.biopha.2021.111785 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"30304_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yjmcc.2013.01.006","volume":"57","author":"C Duerrschmid","year":"2013","unstructured":"Duerrschmid, C. et al. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J. Mol. Cell. Cardiol. 57, 59\u201367. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.01.006 (2013).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"30304_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2249.2005.02840.x","volume":"142","author":"PT Elkington","year":"2005","unstructured":"Elkington, P. T., O\u2019Kane, C. M. & Friedland, J. S. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 142, 12\u201320. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02840.x (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"30304_CR39","doi-asserted-by":"crossref","unstructured":"Yunt, Z. X., Aschner, Y. & Brown, K. K. Biomarkers in IPF. In Idiopathic Pulmonary Fibrosis (eds Swigris, J. J. & Brown, K. K.) 99\u2013112 (Elsevier, 2019).","DOI":"10.1016\/B978-0-323-54431-3.00010-X"},{"key":"30304_CR40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"Takagi, H., Mizuno, Y., Yamamoto, H., Goto, S.-N. & Umemoto, T. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: A meta-analysis of randomized controlled trials. Hypertens. Res. 36, 368\u2013373. https:\/\/doi.org\/10.1038\/hr.2012.196 (2013).","journal-title":"Hypertens. Res."},{"key":"30304_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","volume":"268","author":"T Jostock","year":"2001","unstructured":"Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160\u2013167. https:\/\/doi.org\/10.1046\/j.1432-1327.2001.01867.x (2001).","journal-title":"Eur. J. Biochem."},{"key":"30304_CR42","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41586-023-06034-3","volume":"617","author":"E Pairo-Castineira","year":"2023","unstructured":"Pairo-Castineira, E. et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature 617, 764\u2013768. https:\/\/doi.org\/10.1038\/s41586-023-06034-3 (2023).","journal-title":"Nature"},{"key":"30304_CR43","doi-asserted-by":"publisher","first-page":"e139834","DOI":"10.1172\/jci.insight.139834","volume":"5","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight 5, e139834. https:\/\/doi.org\/10.1172\/jci.insight.139834 (2020).","journal-title":"JCI Insight"},{"key":"30304_CR44","doi-asserted-by":"publisher","first-page":"e0258351","DOI":"10.1371\/journal.pone.0258351","volume":"16","author":"A Lehmann","year":"2021","unstructured":"Lehmann, A. et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS ONE 16, e0258351. https:\/\/doi.org\/10.1371\/journal.pone.0258351 (2021).","journal-title":"PLoS ONE"},{"key":"30304_CR45","doi-asserted-by":"publisher","first-page":"mjac021","DOI":"10.1093\/jmcb\/mjac021","volume":"14","author":"MC Pontelli","year":"2022","unstructured":"Pontelli, M. C. et al. SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients. J. Mol. Cell Biol. 14, mjac021. https:\/\/doi.org\/10.1093\/jmcb\/mjac021 (2022).","journal-title":"J. Mol. Cell Biol."},{"key":"30304_CR46","unstructured":"Nildris, C.-D., Bryan, A. W. & Mark, C. C. Peptidases and the renin\u2013angiotensin system: The alternative angiotensin-(1\u20137) cascade. In Enzyme Inhibitors and Activators (ed. Murat, S.) Ch. 1 (IntechOpen, 2017)."},{"key":"30304_CR47","doi-asserted-by":"crossref","unstructured":"Chappell, M. C. The angiotensin-(1\u20137) axis: Formation and metabolism pathways. In Angiotensin-(1\u20137): A Comprehensive Review (ed. Santos, R. A. S.) 1\u201326 (Springer, 2019).","DOI":"10.1007\/978-3-030-22696-1_1"},{"key":"30304_CR48","doi-asserted-by":"publisher","first-page":"625732","DOI":"10.3389\/fimmu.2021.625732","volume":"12","author":"IO Osman","year":"2021","unstructured":"Osman, I. O. et al. Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1\u20137) is modulated in COVID-19 patients. Front. Immunol. 12, 625732. https:\/\/doi.org\/10.3389\/fimmu.2021.625732 (2021).","journal-title":"Front. Immunol."},{"key":"30304_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1254\/jphs.fp0060801","volume":"102","author":"R Miura","year":"2006","unstructured":"Miura, R. et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J. Pharmacol. Sci. 102, 288\u2013295. https:\/\/doi.org\/10.1254\/jphs.fp0060801 (2006).","journal-title":"J. Pharmacol. Sci."},{"key":"30304_CR50","doi-asserted-by":"publisher","first-page":"e05641","DOI":"10.1016\/j.heliyon.2020.e05641","volume":"6","author":"R Alnajjar","year":"2020","unstructured":"Alnajjar, R., Mostafa, A., Kandeil, A. & Al-Karmalawy, A. A. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon 6, e05641. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05641 (2020).","journal-title":"Heliyon"},{"key":"30304_CR51","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1177\/009127000004001210PubMed","volume":"40","author":"DH Smith","year":"2000","unstructured":"Smith, D. H., Matzek, K. M. & Kempthorne-Rawson, J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J. Clin. Pharmacol. 40, 1380\u20131390. https:\/\/doi.org\/10.1177\/009127000004001210PubMed (2000).","journal-title":"J. Clin. Pharmacol."},{"key":"30304_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0031-1296753PubMed","volume":"56","author":"P Zhang","year":"2006","unstructured":"Zhang, P. et al. Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels. Arzneimittelforschung 56, 569\u2013573. https:\/\/doi.org\/10.1055\/s-0031-1296753PubMed (2006).","journal-title":"Arzneimittelforschung"},{"key":"30304_CR53","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2147\/DDDT.S156492","volume":"12","author":"WY Kang","year":"2018","unstructured":"Kang, W. Y. et al. Pharmacokinetic and bioequivalence study of a telmisartan\/S-amlodipine fixed-dose combination (CKD-828) formulation and co-administered telmisartan and S-amlodipine in healthy subjects. Drug Des. Devel. Ther. 12, 1239\u20131248. https:\/\/doi.org\/10.2147\/DDDT.S156492 (2018).","journal-title":"Drug Des. Devel. Ther."},{"key":"30304_CR54","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3390\/life11080810","volume":"11","author":"P Reus","year":"2021","unstructured":"Reus, P. et al. Characterization of ACE inhibitors and AT1R antagonists with regard to their effect on ACE2 expression and infection with SARS-CoV-2 using a Caco-2 cell model. Life (Basel) 11, 810. https:\/\/doi.org\/10.3390\/life11080810 (2021).","journal-title":"Life (Basel)"},{"key":"30304_CR55","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/pharmaceutics15071891","volume":"15","author":"N Mulgaonkar","year":"2023","unstructured":"Mulgaonkar, N. et al. Montelukast and telmisartan as inhibitors of SARS-CoV-2 Omicron variant. Pharmaceutics 15, 1891. https:\/\/doi.org\/10.3390\/pharmaceutics15071891 (2023).","journal-title":"Pharmaceutics"},{"key":"30304_CR56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.07.014","volume":"72","author":"I Imayama","year":"2006","unstructured":"Imayama, I. et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc. Res. 72, 184\u2013190. https:\/\/doi.org\/10.1016\/j.cardiores.2006.07.014 (2006).","journal-title":"Cardiovasc. Res."},{"key":"30304_CR57","doi-asserted-by":"publisher","first-page":"113980","DOI":"10.1016\/j.bcp.2020.113980","volume":"177","author":"KD Bouknight","year":"2020","unstructured":"Bouknight, K. D. et al. Structural and kinetic evidence of aging after organophosphate inhibition of human cathepsin A. Biochem. Pharmacol. 177, 113980. https:\/\/doi.org\/10.1016\/j.bcp.2020.113980 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"30304_CR58","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.3390\/ijms21218038","volume":"21","author":"J Hrenak","year":"2020","unstructured":"Hrenak, J. & Simko, F. Renin\u2013angiotensin system: An important player in the pathogenesis of acute respiratory distress syndrome. Int. J. Mol. Sci. 21, 8038. https:\/\/doi.org\/10.3390\/ijms21218038 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"30304_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-021-03610-3","volume":"594","author":"Y Finkel","year":"2021","unstructured":"Finkel, Y. et al. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature 594, 240\u2013245. https:\/\/doi.org\/10.1038\/s41586-021-03610-3 (2021).","journal-title":"Nature"},{"key":"30304_CR60","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1039\/b908315d","volume":"5","author":"R de Sousa Abreu","year":"2009","unstructured":"de Sousa Abreu, R., Penalva, L. O., Marcotte, E. M. & Vogel, C. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 5, 1512\u20131526. https:\/\/doi.org\/10.1039\/b908315d (2009).","journal-title":"Mol. Biosyst."},{"key":"30304_CR61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227\u2013232. https:\/\/doi.org\/10.1038\/nrg3185 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"30304_CR62","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/circresaha.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671\u20131681. https:\/\/doi.org\/10.1161\/circresaha.120.317134 (2020).","journal-title":"Circ. Res."},{"key":"30304_CR63","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng, J. et al. Renin\u2013angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microbes Infect. 9, 757\u2013760. https:\/\/doi.org\/10.1080\/22221751.2020.1746200 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"30304_CR64","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","volume":"37","author":"M Duarte","year":"2021","unstructured":"Duarte, M. et al. Telmisartan for treatment of COVID-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine 37, 100962. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100962 (2021).","journal-title":"EClinicalMedicine"},{"key":"30304_CR65","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1053\/j.ajkd.2005.08.034","volume":"46","author":"P Aranda","year":"2005","unstructured":"Aranda, P. et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am. J. Kidney Dis. 46, 1074\u20131079. https:\/\/doi.org\/10.1053\/j.ajkd.2005.08.034 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"30304_CR66","doi-asserted-by":"publisher","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","volume":"379","author":"MJ Jardine","year":"2022","unstructured":"Jardine, M. J. et al. Angiotensin receptor blockers for the treatment of COVID-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ 379, e072175. https:\/\/doi.org\/10.1136\/bmj-2022-072175 (2022).","journal-title":"BMJ"},{"key":"30304_CR67","doi-asserted-by":"publisher","first-page":"E728","DOI":"10.1503\/cmaj.76023","volume":"192","author":"RA Henry","year":"2020","unstructured":"Henry, R. A. Renin\u2013angiotensin\u2013aldosterone system inhibitors to treat COVID-19?. CMAJ 192, E728. https:\/\/doi.org\/10.1503\/cmaj.76023 (2020).","journal-title":"CMAJ"},{"key":"30304_CR68","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/diagnostics13050983","volume":"13","author":"O Zahornacky","year":"2023","unstructured":"Zahornacky, O., Porub\u010din, \u0160, Rovnakova, A. & Jarcuska, P. Multisystem inflammatory syndrome in adults associated with recent infection with COVID-19. Diagnostics (Basel) 13, 983. https:\/\/doi.org\/10.3390\/diagnostics13050983 (2023).","journal-title":"Diagnostics (Basel)"},{"key":"30304_CR69","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/infdis\/jiab490","volume":"224","author":"MJ Peluso","year":"2021","unstructured":"Peluso, M. J. et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 224, 1839\u20131848. https:\/\/doi.org\/10.1093\/infdis\/jiab490 (2021).","journal-title":"J. Infect. Dis."},{"key":"30304_CR70","doi-asserted-by":"publisher","first-page":"e147819","DOI":"10.1172\/jci.insight.147819","volume":"7","author":"I Zaidan","year":"2022","unstructured":"Zaidan, I. et al. Angiotensin-(1\u20137)\/MasR axis promotes migration of monocytes\/macrophages with a regulatory phenotype to perform phagocytosis and efferocytosis. JCI Insight 7, e147819. https:\/\/doi.org\/10.1172\/jci.insight.147819 (2022).","journal-title":"JCI Insight"},{"key":"30304_CR71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41587-020-00796-1","volume":"39","author":"S Trump","year":"2021","unstructured":"Trump, S. et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat. Biotechnol. 39, 705\u2013716. https:\/\/doi.org\/10.1038\/s41587-020-00796-1 (2021).","journal-title":"Nat. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30304-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30304-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:02:39Z","timestamp":1767830559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30304-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30304"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30304-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"720"}}